Pediatric cardiac surgeon Marshall Jacobs is coordinating outcomes research across three congenital heart surgery programs.
At age 12, Austin Cole had a Ross procedure at The Johns Hopkins Hospital to replace his diseased aortic valve. Cole was born with aortic valve stenosis and over the years had multiple balloon valvotomies to open the valve and postpone the open heart surgery that would eventually be required. The delay allowed his body to mature enough to better accommodate the new pulmonary valve that would be put in as part of the Ross procedure.
“It was a major operation. It took me several months to recover,” says Cole, now 18.
However, two years later, the function of the donor pulmonary homograft began to deteriorate. Fortunately, by the time Cole needed a new pulmonary valve, Johns Hopkins pediatric cardiologist Richard Ringel was among the first clinicians in the country to offer a minimally invasive new procedure and a new device to replace pulmonary valves in the cath lab rather than in the OR.
“My recovery was much quicker compared with the operation I had when I was 12,” says Cole. “It has definitely made a big difference.”
Cole’s experience is an example of the many refinements that have been made in treating congenital heart problems since the world’s first “blue baby” operation was performed at Johns Hopkins in 1944. The minimally invasive valve procedure is also helping people born with tetralogy of Fallot. Although the blue baby operation was a lifesaving turning point, it later became clear that many patients would need subsequent procedures.
“They have a valve that’s too small or badly obstructed, and we need to create an opening, sacrificing the valve to get over the obstruction,” says Johns Hopkins Cardiac Surgery Director Duke Cameron. “We’ve learned that over time, the opening we created is leaking and the right side of the heart is struggling.”
Because of that, Cameron says it’s important to replace the pulmonary valve before the regurgitation causes the heart to become enlarged and weak. That knowledge has influenced how the operation for tetralogy of Fallot now is performed.
“Today, we bend over backwards to preserve the patient’s own valve,” says Cameron. “It’s a balance to tolerate the slight blockage in order to avoid a lot of leakage down the road.”
Among the keys for further refining treatment for congenital heart defects, says Cameron, is evaluating outcomes through databases that combine the experience of many large programs. Cameron has recruited pediatric cardiac surgeon Marshall Jacobs to coordinate outcomes research and share experience and expertise across the congenital heart surgery programs at The Johns Hopkins Hospital, All Children’s Hospital Johns Hopkins Medicine in St. Petersburg, Florida, and Florida Hospital for Children in Orlando.
“Better medical and surgical techniques and greater understanding of the disease processes have led to a much improved outlook and quality of life,” says Jacobs. “There are now as many adults living with congenital heart disease as there are infants and children. Our goal is to develop ways to provide even better care of these patients.”